Innovation and Technology Payment

The Innovation and Technology Payment (ITP) programme supports the NHS to adopt innovations by removing some of the financial and procurement barriers to introducing new technologies.

It is a competitive process for innovations and technologies that have already proved their clinical effectiveness and are ready to be rolled out nationally.

The 2019/20 ITP programme builds on the Innovation and Technology Tariff (ITT) and ITP 2018/19 and is supporting the following themes:

  • Non-invasive vagus nerve stimulation therapy for the treatment of cluster headaches.
  • Absorbable spacer to reduce rectum radiation exposure during prostate radiation therapy.
  • Placental growth factor (PIGF) based test for the rule‑out of pre-eclampsia
  • High sensitivity troponin assay in a rapid rule out protocol for acute myocardial infarction.

Additionally, two themes will be supported through the Evidence Generation Fund. These themes will have a more limited roll-out and more intensive evaluation support:

  • Digital apps to support emergency/crisis mental health assessments.
  • Interoperable personal health record tool.

The Innovation Technology Tariff of 2017/18 and the Innovation Technology Payment 2018/19 will continue to be supported during 2019/20. Details of these innovations can be found in the technical notes posted here:

SpaceOAR is a gel injection which reduces the effects of radiation for prostate cancer patients and has been supported with funding through the ITP programme. Prostate cancer patients in Southampton are now benefitting from this medical breakthrough. University Hospital Southampton is currently trialling SpaceOAR and was featured on local TV and newspapers, including BBC South Today.